{"disease":{"id":"bipolar-disorder-manic","name":"bipolar disorder manic"},"drugs":{"marketed":[{"drug_id":"cariprazine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vraylar","generic_name":"CARIPRAZINE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":"3267","mechanism":"Vraylar works by selectively blocking the D3 dopamine receptor, which helps regulate mood and behavior."},{"drug_id":"aripiprazole","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abilify","generic_name":"aripiprazole","company_name":"Generic (originally Otsuka/BMS)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Third-generation antipsychotic (D2 partial agonist)","quality_score":63,"revenue":"3000","mechanism":"Third-generation antipsychotic that acts as a partial agonist at D2 and 5-HT1A receptors, stabilizing dopamine activity rather than simply blocking it."},{"drug_id":"olanzapine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyprexa","generic_name":"olanzapine","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":"300","mechanism":null},{"drug_id":"chlorpromazine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thorazine","generic_name":"chlorpromazine","company_name":"Generic (originally Rhône-Poulenc/Sanofi)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Sphingomyelin phosphodiesterase, 5-hydroxytryptamine receptor 1E","drug_class":"Typical antipsychotic (first-generation, phenothiazine)","quality_score":31,"revenue":null,"mechanism":""},{"drug_id":"lithium-citrate","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithium Citrate","generic_name":"LITHIUM CITRATE","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Glycogen synthase kinase-3","drug_class":"lithium","quality_score":10,"revenue":null,"mechanism":"Lithium Citrate works by inhibiting glycogen synthase kinase-3, a key enzyme involved in the regulation of various cellular processes."},{"drug_id":"quetiapine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seroquel","generic_name":"quetiapine","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"sodium valproate","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epilim","generic_name":"sodium valproate","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"asenapine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Saphris","generic_name":"ASENAPINE","company_name":"Hisamitsu","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2C","drug_class":"Atypical Antipsychotic [EPC]","quality_score":67,"revenue":null,"mechanism":"Saphris works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2C."},{"drug_id":"carbamazepine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tegretol","generic_name":"carbamazepine","company_name":"Novartis AG (originally Geigy)","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"Mood Stabilizer [EPC]","quality_score":62,"revenue":null,"mechanism":"Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain."},{"drug_id":"risperidone","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Risperdal","generic_name":"risperidone","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":null,"mechanism":"Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors for schizophrenia and bipolar disorder."},{"drug_id":"ziprasidone","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Geodon","generic_name":"ziprasidone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aspartate aminotransferase, cytoplasmic, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical antipsychotic (second-generation)","quality_score":10,"revenue":null,"mechanism":"Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors with the least metabolic side effects in its class."},{"drug_id":"carbamazepin","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carbamazepin","company_name":"Enanta Pharmaceuticals, Inc","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"valproic-acid","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depakene","generic_name":"valproic acid","company_name":"Generic (originally Abbott/AbbVie)","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"Anti-epileptic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":"Broad-spectrum anticonvulsant that enhances GABA activity, blocks sodium and calcium channels, and inhibits histone deacetylase."},{"drug_id":"lithium","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithobid","generic_name":"lithium carbonate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3","drug_class":"Mood stabilizer","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"lithium-carbonate","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithium Carbonate","generic_name":"LITHIUM CARBONATE","company_name":"","drug_phase":"marketed","molecular_target":"Glycogen synthase kinase-3","drug_class":"lithium carbonate","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"seroquel","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Seroquel","company_name":"University of Pittsburgh","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"quetiapin","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapin","company_name":"Sykehuset Innlandet HF","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"risperdal","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Risperdal","company_name":"Ohio State University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zyprexa","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zyprexa","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"samidorphan","indication_name":"Bipolar I Disorder - Acute Manic or Mixed Episodes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lybalvi","generic_name":"SAMIDORPHAN","company_name":"Alkermes Inc","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":null,"mechanism":"Lybalvi blocks the action of opioids at their receptor sites in the brain."},{"drug_id":"divalproex","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Divalproex","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"samidorphan-l-malate","indication_name":"Bipolar I Disorder - Acute Manic or Mixed Episodes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SAMIDORPHAN L-MALATE","company_name":"","drug_phase":"marketed","molecular_target":"dopamine and serotonin type 2 (5HT2) receptors, opioid receptors","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":null,"mechanism":"Olanzapine's efficacy may be due to dopamine and serotonin type 2 antagonism, while samidorphan acts through opioid receptor antagonism."},{"drug_id":"abilify","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abilify","company_name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":19,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":23,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03257865","title":"A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":333,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT03259555","title":"A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":322,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT04399070","title":"The Effect of S-ketamine for Patients Undergoing Electroconvulsive Therapy (ECT)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Yan Qiu","has_results":false},{"nct_id":"NCT04563910","title":"Impact of Duration of Untreated Manic Episodes on Clinical Outcome","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT03857438","title":"Correlation of Audiovisual Features With Clinical Variables and Neurocognitive Functions in Bipolar Disorder, Mania","phase":"","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Istanbul Saglik Bilimleri University","has_results":false},{"nct_id":"NCT04643210","title":"Management of my Bipolarity Intervention in Bipolar Disorder Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Cyprus University of Technology","has_results":false},{"nct_id":"NCT03013400","title":"Ebselen as an add-on Treatment in Hypo/Mania","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT03160664","title":"Magnetic Seizure Therapy for Bipolar Mania","phase":"NA","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT04874974","title":"Feasibility of a Novel Process-based Treatment for Patients With Psychosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Max-Planck-Institute of Psychiatry","has_results":false},{"nct_id":"NCT06426134","title":"Ketosis Impact on Signs & Symptoms of Schizophrenia and Bipolar disorderS","phase":"NA","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT04420793","title":"Voice Changes During ECT","phase":"","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Medical University of South Carolina","has_results":false},{"nct_id":"NCT04058249","title":"Accelerated Theta Burst Stimulation for Inpatients With Bipolar Disorder","phase":"NA","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Stanford University","has_results":true}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}